Lactose-free, non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine for the treatment of symptomatic dermographism, dermatitis, cough/flu symptoms and histamine-related disorders

摘要

A pharmaceutical composition for the treatment of histamine-induced disorders, Stable pharmaceutical compositions of descarboethoxyloratadine (DCL), a metabolic derivative of loratadine, for the treatment of allergic rhinitis and other histamine-induced disorders are disclosed. The compositions are formulated to avoid the incompatibility between DCL and reactive excipients such as lactose and other mono- and di-saccharides. A therapeutically effective amount of descarboethoxyloratadine, in blended or granulated form, including lactose-free, non-hygroscopic and anhydrous stable pharmaceutical compositions of DCL is disclosed.